Lilly, UnitedHealth Partner in Study of Bamlanivimab in Covid-19
December 04 2020 - 8:51AM
Dow Jones News
By Michael Dabaie
Eli Lilly & Co. and UnitedHealth Group Inc. said they are in
a partnership to conduct a study under real-world conditions of
bamlanivimab, or LY-CoV555, in high-risk, Covid-19 infected
individuals.
The study will treat a large, diverse population of high-risk
individuals for Covid-19 with bamlanivimab under real-world
conditions with a goal of reducing the severity of illness and
hospitalizations, the companies said Friday.
Bamlanivimab recently received emergency use authorization from
the U.S. Food and Drug Administration for treatment of mild to
moderate Covid-19 patients at high risk for progressing to severe
Covid-19 and hospitalization, Lilly said.
The trial will evaluate bamlanivimab versus a control in people
that meet the emergency use authorization criteria.
It will draw on both UnitedHealth's UnitedHealthcare health
benefits business as well as its Optum health services business to
detect and treat high-risk symptomatic patients who test positive
for Covid-19, including daily symptom tracking, in-home SARS-CoV-2
testing and in-home infusion services.
"While bamlanivimab is authorized for emergency use based on the
efficacy and safety data accumulated to date, larger pragmatic
studies in diverse populations can help us further understand the
efficacy and safety of SARS-CoV-2 neutralizing antibodies in real
world settings," said Daniel Skovronsky, Lilly's chief scientific
officer and president of Lilly Research Laboratories.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
December 04, 2020 08:36 ET (13:36 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
UnitedHealth (NYSE:UNH)
Historical Stock Chart
From Mar 2024 to Apr 2024
UnitedHealth (NYSE:UNH)
Historical Stock Chart
From Apr 2023 to Apr 2024